| NCT06995677 | Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer | RECRUITING | PHASE2 | 2025-06-27 | 2028-09 | 2028-02 |
| NCT06915753 | Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations | RECRUITING | PHASE1 | 2025-04-24 | 2028-09 | 2028-01 |
| NCT06842355 | A Study of TYRA-300 in Children With Achondroplasia: BEACH301 | RECRUITING | PHASE2 | 2025-03-04 | 2030-06 | 2030-01 |
| NCT06160752 | Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations | RECRUITING | PHASE1 | 2023-11-22 | 2027-09 | 2026-09 |
| NCT06006702 | A Relative Bioavailability and Food Effect Study of TYRA-300-B01 Capsule and Tablet Formulations in Healthy Adult Participants | ACTIVE_NOT_RECRUITING | PHASE1 | 2023-10-16 | 2025-07 | 2025-05 |
| NCT05544552 | Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations | RECRUITING | PHASE1, PHASE2 | 2022-11-22 | 2027-06 | 2026-11 |